Guangdong Zhongsheng Pharmaceutical (002317.SZ) subsidiary ZSP1601 tablets included in breakthrough therapy drug program
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that recently, according to the public notice issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, ZSP1601 tablets, a Class 1 innovative drug independently developed by the company's controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., have been included in the breakthrough therapy drug program by the CDE. The proposed indication for the drug is metabolic dysfunction-associated steatohepatitis (MASH).
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that recently, according to the public information released by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, ZSP1601 tablets, a Class 1 innovative drug independently developed by the company's controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., have been included in the breakthrough therapy drug program by the CDE. The proposed indication for this drug is metabolic dysfunction-associated steatohepatitis (MASH).
Related Articles
Sinolink: A-share "imperfect bottom" rebound front-run; recommend allocation around three approaches including oversold rebound
ALCO HOLDINGS (00328) proposes to place up to 57,278,400 shares at a discount of approximately 17.7% to raise net proceeds of approximately HK$21 million
MICROPORT(00853): Jonathan W. Chen Appointed as Executive Director
Sinolink: A-share "imperfect bottom" rebound front-run; recommend allocation around three approaches including oversold rebound
ALCO HOLDINGS (00328) proposes to place up to 57,278,400 shares at a discount of approximately 17.7% to raise net proceeds of approximately HK$21 million
MICROPORT(00853): Jonathan W. Chen Appointed as Executive Director
